• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞增多症是年轻的真性红细胞增多症和原发性血小板增多症患者复发性动脉血栓形成的一个危险因素。

Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.

机构信息

The Institute of Hematology, Catholic University, Rome, Italy.

出版信息

Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593.

DOI:10.1002/ajh.21593
PMID:20052743
Abstract

There is evidence that leukocytosis is associated with an increased risk of first thrombosis in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Whether it is a risk factor for recurrent thrombosis too is currently unknown. In the frame of a multicenter retrospective cohort study, we recruited 253 patients with PV (n = 133) or ET (n = 120), who were selected on the basis of a first arterial (70%) or venous major thrombosis (27.6%) or both (2.4%), and who were not receiving cytoreduction at the time of thrombosis. The probability of recurrent thrombosis associated with the leukocyte count recorded at the time of the first thrombosis was estimated by a receiver operating characteristic analysis and a multivariable Cox proportional hazards regression model. Thrombosis recurred in 78 patients (30.7%); multivariable analysis showed an independent risk of arterial recurrence (hazard ratio [HR] 2.16, 95% CI 1.12-4.18) in patients with a leukocyte count that was >12.4 x 10(9)/L at the time of the first thrombotic episode. The prognostic role for leukocytosis was age-related, as it was only significant in patients that were aged <60 years (HR for arterial recurrence 3.35, 95% CI 1.22-9.19).

摘要

有证据表明,白细胞增多与真性红细胞增多症(PV)和原发性血小板增多症(ET)患者首次血栓形成的风险增加有关。它是否也是复发性血栓形成的危险因素目前尚不清楚。在一项多中心回顾性队列研究中,我们招募了 253 名 PV(n=133)或 ET(n=120)患者,这些患者是基于首次动脉(70%)或静脉主要血栓形成(27.6%)或两者(2.4%)而选择的,并且在血栓形成时未接受细胞减少治疗。通过接收者操作特征分析和多变量 Cox 比例风险回归模型估计首次血栓形成时记录的白细胞计数与复发性血栓形成的概率之间的相关性。78 名患者(30.7%)发生了血栓复发;多变量分析显示,在首次血栓发作时白细胞计数>12.4 x 10(9)/L 的患者中,动脉复发的风险独立增加(危险比[HR]2.16,95%置信区间 1.12-4.18)。白细胞增多的预后作用与年龄相关,因为它仅在年龄<60 岁的患者中具有显著性(动脉复发的 HR 为 3.35,95%置信区间 1.22-9.19)。

相似文献

1
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.白细胞增多症是年轻的真性红细胞增多症和原发性血小板增多症患者复发性动脉血栓形成的一个危险因素。
Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593.
2
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.真性红细胞增多症和原发性血小板增多症患者的复发性血栓形成:发病率、危险因素及治疗效果。
Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11.
3
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.低危原发性血小板增多症和真性红细胞增多症患者诊断时的白细胞增多与随后发生血栓的风险。
Cancer. 2009 Dec 15;115(24):5740-5. doi: 10.1002/cncr.24664.
4
Leukocytosis and risk stratification assessment in essential thrombocythemia.原发性血小板增多症中的白细胞增多及风险分层评估
J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. Epub 2008 Apr 28.
5
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.原发性血小板增多症和真性红细胞增多症患者中血小板介导的红斑性肢痛症、脑、眼及冠状动脉微血管缺血和血栓形成表现:一种独特的阿司匹林反应性和华法林抵抗性动脉血栓形成倾向。
Platelets. 2006 Dec;17(8):528-44. doi: 10.1080/09537100600758677.
6
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.携带 JAK2 V617F 突变纯合子的原发性血小板增多症患者复发性血栓形成风险增加。
Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7.
7
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中因子V莱顿突变携带者与静脉血栓栓塞症
Am J Hematol. 2002 Sep;71(1):1-6. doi: 10.1002/ajh.10153.
8
Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.真性红细胞增多症中的白细胞增多和特发性血小板增多症中的脾肿大是出血的独立危险因素。
Eur J Haematol. 2013 Mar;90(3):228-36. doi: 10.1111/ejh.12064.
9
Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中的动脉狭窄与动脉粥样硬化血栓形成事件
Rom J Intern Med. 2006;44(4):397-406.
10
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.白细胞增多对 532 例原发性血小板增多症患者血栓风险和生存的影响:一项回顾性研究。
Ann Hematol. 2011 Aug;90(8):933-8. doi: 10.1007/s00277-010-1154-3. Epub 2011 Feb 2.

引用本文的文献

1
Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021.真性红细胞增多症的真实世界特征及治疗模式:2020年至2021年台湾地区一项基于人群的横断面研究
Ther Adv Hematol. 2025 Jul 28;16:20406207251359651. doi: 10.1177/20406207251359651. eCollection 2025.
2
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.探索真性红细胞增多症的血栓栓塞危险因素:从当前证据到PROSPERO研究设计
Ann Hematol. 2025 Jul 18. doi: 10.1007/s00277-025-06466-z.
3
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.
ELN临床体征和症状对一线羟基脲治疗的真性红细胞增多症患者血栓形成风险的影响。
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02646-y.
4
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.一项在美国和加拿大开展的多中心研究,旨在评估罗培法新干扰素α-2b-njft治疗原发性血小板增多症患者的疗效、安全性和耐受性:EXCEED-ET试验。
Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025.
5
Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates.原发性骨髓纤维化中的嗜碱性粒细胞增多和嗜酸性粒细胞增多:表型、基因型及预后相关性
Blood Cancer J. 2025 Apr 21;15(1):72. doi: 10.1038/s41408-025-01285-x.
6
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.PARADIGM-PV:一项随机、多中心4期研究,旨在评估聚乙二醇干扰素α-2b治疗低危或高危真性红细胞增多症患者的疗效和安全性。
Ann Hematol. 2025 Jan;104(1):335-345. doi: 10.1007/s00277-025-06185-5. Epub 2025 Jan 13.
7
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.聚乙二醇干扰素α-2b治疗真性红细胞增多症的药代动力学、疗效和安全性的种族敏感性分析。
Front Pharmacol. 2024 Sep 24;15:1455979. doi: 10.3389/fphar.2024.1455979. eCollection 2024.
8
Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications.真性红细胞增多症中的全身炎症指数及其预后意义。
J Clin Med. 2024 Jul 30;13(15):4459. doi: 10.3390/jcm13154459.
9
Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score system.真性红细胞增多症中血栓形成的预测:基于多因素的预后评分系统的开发与验证
Res Pract Thromb Haemost. 2023 Mar 28;7(3):100132. doi: 10.1016/j.rpth.2023.100132. eCollection 2023 Mar.
10
Prognostication in myeloproliferative neoplasms, including mutational abnormalities.骨髓增殖性肿瘤的预后评估,包括突变异常。
Blood Res. 2023 Apr 30;58(S1):S37-S45. doi: 10.5045/br.2023.2023038. Epub 2023 Mar 16.